BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 22854115)

  • 1. Lynch syndrome in a predominantly Afrocentric population: a clinicopathological and genetic study.
    Plummer JM; Chin SN; Aronson M; Graham RP; Williams NP; Bapat B; Wharfe G; Pollett A; Gallinger S
    Can J Surg; 2012 Oct; 55(5):294-300. PubMed ID: 22854115
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Screening for germline mutations of MLH1, MSH2, MSH6 and PMS2 genes in Slovenian colorectal cancer patients: implications for a population specific detection strategy of Lynch syndrome.
    Berginc G; Bracko M; Ravnik-Glavac M; Glavac D
    Fam Cancer; 2009; 8(4):421-9. PubMed ID: 19526325
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical and molecular detection of inherited colorectal cancers in northeast Italy: a first prospective study of incidence of Lynch syndrome and MUTYH-related colorectal cancer in Italy.
    Urso E; Agostini M; Pucciarelli S; Rugge M; Bertorelle R; Maretto I; Bedin C; D'Angelo E; Mescoli C; Zorzi M; Viel A; Bruttocao G; Ferraro B; Erroi F; Contin P; De Salvo GL; Nitti D
    Tumour Biol; 2012 Jun; 33(3):857-64. PubMed ID: 22278153
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Taiwan hospital-based detection of Lynch syndrome distinguishes 2 types of microsatellite instabilities in colorectal cancers.
    Chang SC; Lin PC; Yang SH; Wang HS; Liang WY; Lin JK
    Surgery; 2010 May; 147(5):720-8. PubMed ID: 20045164
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combined Microsatellite Instability, MLH1 Methylation Analysis, and Immunohistochemistry for Lynch Syndrome Screening in Endometrial Cancers From GOG210: An NRG Oncology and Gynecologic Oncology Group Study.
    Goodfellow PJ; Billingsley CC; Lankes HA; Ali S; Cohn DE; Broaddus RJ; Ramirez N; Pritchard CC; Hampel H; Chassen AS; Simmons LV; Schmidt AP; Gao F; Brinton LA; Backes F; Landrum LM; Geller MA; DiSilvestro PA; Pearl ML; Lele SB; Powell MA; Zaino RJ; Mutch D
    J Clin Oncol; 2015 Dec; 33(36):4301-8. PubMed ID: 26552419
    [TBL] [Abstract][Full Text] [Related]  

  • 6. BRAF mutation analysis is a valid tool to implement in Lynch syndrome diagnosis in patients classified according to the Bethesda guidelines.
    Molinari F; Signoroni S; Lampis A; Bertan C; Perrone F; Sala P; Mondini P; Crippa S; Bertario L; Frattini M
    Tumori; 2014; 100(3):315-20. PubMed ID: 25076244
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Extended microsatellite analysis in microsatellite stable, MSH2 and MLH1 mutation-negative HNPCC patients: genetic reclassification and correlation with clinical features.
    Schiemann U; Müller-Koch Y; Gross M; Daum J; Lohse P; Baretton G; Muders M; Mussack T; Kopp R; Holinski-Feder E
    Digestion; 2004; 69(3):166-76. PubMed ID: 15118395
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comprehensive molecular analysis of mismatch repair gene defects in suspected Lynch syndrome (hereditary nonpolyposis colorectal cancer) cases.
    Mueller J; Gazzoli I; Bandipalliam P; Garber JE; Syngal S; Kolodner RD
    Cancer Res; 2009 Sep; 69(17):7053-61. PubMed ID: 19690142
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lynch syndrome in Tunisia: first description of clinical features and germline mutations.
    Moussa SA; Moussa A; Kourda N; Mezlini A; Abdelli N; Zerimech F; Najjar T; Jilani SB; Porchet N; Ayed FB; Manai M; Buisine MP
    Int J Colorectal Dis; 2011 Apr; 26(4):455-67. PubMed ID: 21311894
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Target gene mutational pattern in Lynch syndrome colorectal carcinomas according to tumour location and germline mutation.
    Pinheiro M; Pinto C; Peixoto A; Veiga I; Lopes P; Henrique R; Baldaia H; Carneiro F; Seruca R; Tomlinson I; Kovac M; Heinimann K; Teixeira MR
    Br J Cancer; 2015 Aug; 113(4):686-92. PubMed ID: 26247575
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identification of mismatch repair gene mutations in young patients with colorectal cancer and in patients with multiple tumours associated with hereditary non-polyposis colorectal cancer.
    Niessen RC; Berends MJ; Wu Y; Sijmons RH; Hollema H; Ligtenberg MJ; de Walle HE; de Vries EG; Karrenbeld A; Buys CH; van der Zee AG; Hofstra RM; Kleibeuker JH
    Gut; 2006 Dec; 55(12):1781-8. PubMed ID: 16636019
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Microsatellite instability and novel mismatch repair gene mutations in northern Chinese population with hereditary non-polyposis colorectal cancer.
    Sheng JQ; Chan TL; Chan YW; Huang JS; Chen JG; Zhang MZ; Guo XL; Mu H; Chan AS; Li SR; Yuen ST; Leung SY
    Chin J Dig Dis; 2006; 7(4):197-205. PubMed ID: 17054581
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prevalence of alterations in DNA mismatch repair genes in patients with young-onset colorectal cancer.
    Limburg PJ; Harmsen WS; Chen HH; Gallinger S; Haile RW; Baron JA; Casey G; Woods MO; Thibodeau SN; Lindor NM
    Clin Gastroenterol Hepatol; 2011 Jun; 9(6):497-502. PubMed ID: 21056691
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lynch syndrome (hereditary nonpolyposis colorectal cancer) diagnostics.
    Lagerstedt Robinson K; Liu T; Vandrovcova J; Halvarsson B; Clendenning M; Frebourg T; Papadopoulos N; Kinzler KW; Vogelstein B; Peltomäki P; Kolodner RD; Nilbert M; Lindblom A
    J Natl Cancer Inst; 2007 Feb; 99(4):291-9. PubMed ID: 17312306
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A mononucleotide markers panel to identify hMLH1/hMSH2 germline mutations.
    Pedroni M; Roncari B; Maffei S; Losi L; Scarselli A; Di Gregorio C; Marino M; Roncucci L; Benatti P; Ponti G; Rossi G; Menigatti M; Viel A; Genuardi M; de Leon MP
    Dis Markers; 2007; 23(3):179-87. PubMed ID: 17473388
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison between universal molecular screening for Lynch syndrome and revised Bethesda guidelines in a large population-based cohort of patients with colorectal cancer.
    Pérez-Carbonell L; Ruiz-Ponte C; Guarinos C; Alenda C; Payá A; Brea A; Egoavil CM; Castillejo A; Barberá VM; Bessa X; Xicola RM; Rodríguez-Soler M; Sánchez-Fortún C; Acame N; Castellví-Bel S; Piñol V; Balaguer F; Bujanda L; De-Castro ML; Llor X; Andreu M; Carracedo A; Soto JL; Castells A; Jover R
    Gut; 2012 Jun; 61(6):865-72. PubMed ID: 21868491
    [TBL] [Abstract][Full Text] [Related]  

  • 17. "Null pattern" of immunoreactivity in a Lynch syndrome-associated colon cancer due to germline MSH2 mutation and somatic MLH1 hypermethylation.
    Hagen CE; Lefferts J; Hornick JL; Srivastava A
    Am J Surg Pathol; 2011 Dec; 35(12):1902-5. PubMed ID: 22067334
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Spectrum of MLH1 and MSH2 mutations in Chilean families with suspected Lynch syndrome.
    Alvarez K; Hurtado C; Hevia MA; Wielandt AM; de la Fuente M; Church J; Carvallo P; López-Köstner F
    Dis Colon Rectum; 2010 Apr; 53(4):450-9. PubMed ID: 20305446
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Risk Factors Associated with Colorectal Cancer in a Subset of Patients with Mutations in MLH1 and MSH2 in Taiwan Fulfilling the Amsterdam II Criteria for Lynch Syndrome.
    Kamiza AB; Hsieh LL; Tang R; Chien HT; Lai CH; Chiu LL; Lo TP; Hung KY; Wang CY; You JF; Hsiung CA; Yeh CC
    PLoS One; 2015; 10(6):e0130018. PubMed ID: 26053027
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Yield of routine molecular analyses in colorectal cancer patients ≤70 years to detect underlying Lynch syndrome.
    van Lier MG; Leenen CH; Wagner A; Ramsoekh D; Dubbink HJ; van den Ouweland AM; Westenend PJ; de Graaf EJ; Wolters LM; Vrijland WW; Kuipers EJ; van Leerdam ME; Steyerberg EW; Dinjens WN;
    J Pathol; 2012 Apr; 226(5):764-74. PubMed ID: 22081473
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.